RARE LIVER DISEASE

Gilead posts quarterly loss on acquisition charge, revenue rises 5%

​Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, while revenue rose 5% on higher HIV, oncology and liver disease treatment sales.